Twist Bioscience vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies synthetic genes to 3,000+ customers across biotech, pharma, and AgBio.
About
Twist Bioscience was founded in 2013 in San Francisco by Emily Leproust, Bill Banyai, and Bill Peck, pioneering a silicon-based DNA synthesis platform that writes synthetic DNA at a fraction of the cost and error rate of conventional methods. By printing DNA on silicon wafers using a semiconductor-like process, Twist dramatically reduced the cost of synthetic genes from hundreds to single-digit dollars per gene, democratizing access to DNA writing for the life sciences.\n\nTwist serves over 3,000 customers across biopharmaceuticals, academic research, agriculture, and industrial biotechnology, offering synthetic genes, variant libraries, DNA data storage oligos, and antibody libraries for drug discovery. The company reported $376.6 million in FY2025 revenue, up 20% from $313 million in FY2024, driven by strong growth in its biopharma and drug discovery segments. Twist also operates a growing antibody drug discovery business, providing synthetic antibody libraries that power next-generation therapeutic discovery programs.\n\nTwist has a supply agreement with Ginkgo Bioworks for synthetic DNA to fuel Ginkgo's cell engineering platform, revised in 2025. The company is executing toward profitability, with improving gross margins as manufacturing scale increases. Its silicon-based DNA synthesis platform positions it as critical infrastructure for the emerging bioeconomy, synthetic biology, and DNA data storage industries.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Twist Bioscience vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.